Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Only a fool would buy at these levels, knowing Aspire runs out if it declines another~35%(to 0.25). A rise of 35% from .38 puts us at .513.
How long ago were we there(at 0.513)? This company needs leaders with b.... to steer us out of this tailspin. The crew of this capsule are the only ones with ejection seats who have the chance to land safely if this crashes. Will continue later, putting my oxygen mask back on...
He hasn't lost a cent. Show your math please.
Thomas,
A joke I think not(but get your point). A joke is something that someone says to cause amusement or laughter, especially a story with a funny punchline. One is quite willing to pay to hear jokes at a comedy club without the expectation that they are going to leave the club with more money than they went in with. Investing in ipix is not a joke. However, I can think of more appropriate words.
6m$b,
Stop your nonsense.
Leo could have just overslept today and is, again, late for work.
"The poster you're probably referring to is correct about that. Keep in mind, the company also expected the results by now. Clearly it's taking longer than expected and hence the "overdue". The mistake is assuming that overdue results means they're bad. It just means they're taking longer than expected. Trials can be unpredictable. The recruiting was also slower than expected.
I was that poster, and the drug referred to was Ixekizumab (a.k.a Taltz, Eli Lilly's ph2 (don't think I mentioned company or drug by name)) which has been approved for moderate to severe plaque psoriasis(and also psoritic arthritis(in Europe at least, not sure of U.S) after completing a phase 3 following the ph 2.
Anyhow what I also did not mention was that trial, Lilly's ph 2 ixekizumab (Taltz) also had 32 (2 po, 30 so) total outcome measures vs ipix's 11 (2 po, 9 so). Also not noted was 10 of Lilly's outcome measure endpoints in that trial had durations of at least 240 weeks(~4yr,1 month), with one of those 10 having an outcome measure duration of 344 weeks(6.6 years).
Meanwhile, I stopped searching after PP's poignant post about (I'm paraphrasing) "the never ending search, and how many reviews he/she has done". But, prior to PP's post, I found one ph 2 study that announced results 42 days after completion(Metriopharma, drug MP1032) which had total endpoints of 9 with an estimated 44 patients(vs actual in all other assessments), and a Valeant ph3 study IDP-118 where results were announced 192 days after completion(217 patient study, 1 primary endpoint(po), zero secondary endpoints(so).
Thank you PP for sharing your experience.
The many ways of analyzing.
Boo,
Only a fool would buy at these levels, knowing Aspire runs out if it declines another~39%(to 0.25). A rise of 39% from .41 puts us at .5699.
How long ago were we there(at 0.5699)? This company needs leaders with b.... to steer us out of this tailspin. One flew himself into it, the other managed to avoid it(tailspin)
https://uk.reuters.com/article/uk-pennsylvania-airplane-pilot/angels-and-training-help-former-fighter-pilot-save-southwest-flight-idUKKBN1HP0GZ
Hope he recovers, and is able to rudder us up, but the ground does appear closer, at least from my window.
glta
George,
Worthy thought. Hope you cc'd Leo.
Might the negogiations be sounding like this?
The rate of response from ihub board members has declined, drastically, over the past few weeks. Why?
You ask, "Are we talking to the FDA re: a phase 3 for any of the "B" indications?"
Get the answer from the horses mouth.
You can reach the CEO via phone at 978.921.4125, or email leo@ipharmainc.com
He typically responds.
LR,
Well stated.
TY
tryz,
The term "coiled"has been used to describe it many times over the years, at much higher prices.
The ceo/cfo is the one who negotiated the Aspire agreement. It must have been he who put the draw threshold at $0.25. No?
Right now this is sunk, not coiled(examine the charts). Hopefully we cross an ocean floor volcano, which erupts to blow us out of these waters, b4 we settle into the likes of the Mariani trench.
Can't say much more than this...
Yoopers61,
"Sullivan’s got till Nov 5th of this year to exercise their options. A deal will be done."
They may have already done so.
"Take care of the pence, for the pounds shall take care of themselves."
A wise man once said:
"To contract new debt is not the way to pay old ones."
You state:"The big news could come any day and with Leo wanting to wipe out that shorts I believe he will do everything possible so they don't have a chance to react before it is too late for them and thus that will include those on the sidelines as well."
Have you submitted an inquest to Leo, or corresponded with him, in any way, within the past month, as to what is happening?
I have.
George,
I do declare that none of your year long pronouncements, have rung true.
Please counter my statement with your verification/acknowledgement that your statements have rung true(sp shall triple/P is worth 10B, .
Thx
?
r u kidding me/ Total mis-direction.
WHO on this BOARD has ever discussed Asthma?
CC M. Sullivan
Yooper61,
"Sullivan took shares as payment with just B-ABSSSI results. They saw the offers for B before B-UP and B-OM. They are not speculators."
They (Ashcroft & Sullivan) became part and parcel to ipix(Celluceutix at the time) arguing FOR them (celluceutix(now Innovation Pharmaceuticals)).
Please provide your proof that ":Sullivan took shares as payment with just B-ABSSSI results."
thx
My remaining shares I've held to sue, fyi.
petemantx,
If the current litany of negative posts actually convince anyone to sell their shares, then they deserve to get fleeced as the case for why IPIX will succeed has been made in such terms that anybody with a hint of intelligence should be able to see our drugs are the real deal.
Are you suggesting it has been wise to hold, rather than selling at higher prices and buying back at later dates, or now?- I sold some , at a loss, and would/do not suggest anyone buy now, based on past performance.
If results prevail as George, and some others estimate, I'll gladly buy back in on the rise.
You seem to imply that "fleecing" is going on, one way or the other(who is the culprit). That is why I've stated in the past that M. Sullivan shall be our savior, or our salvation.
Sullivan's reputation is on the line.
And I'm a long (unfortunately), but do ask questions.
Denonate,
" The market is not scientifically driven. People should analyze the fundamentals, not the stock price."
I believe, in today's day and age, investor's approach is via many angles. Long time fundamentals(accounting, managerial, sales, results,pe's, pu's, etc) are now also analyzed, some what scientifically, by algorithm's, etc.
Science has, however somewhat, entered the market.
Detonate,
"In the end it will facts that determine the IPIX share price."
I would include time & money, not just facts.
A wise man once said:
"Remember that Time is Money. He that can earn Ten Shillings a Day by his Labour, and goes abroad, or sits idle one half of that Day, tho’ he spends but Sixpence during his Diversion or Idleness, ought not to reckon That the only Expence; he has really spent or rather thrown away Five Shillings besides."
"Big Pharma's Strategy Is Music to Biotech Investors' Ears
Big Pharma bosses say they are willing to invest for the long run. That means high prices for promising biotech stocks aren't likely to fall any time soon."
Perhaps some BP's, not all. Article out today quoted Pfizer CEO
"Both Mr. Read and Chief Financial Officer Frank D'Amelio downplayed the possibility of finding growth by splitting up the company or doing a major deal, moves for which they had previously expressed more support.
"I don't see we need a transformative deal," Mr. Read said during the call. "The best investment we have now is in our own pipeline."
https://ih.advfn.com/p.php?pid=nmona&article=77311883
Read is Phizer's CEO.
All I know is ipix performance is not the sound of music. More like fingernails on a chalk board.
LilKahuna,
Please do not insinuate that I'm content with ipix's management, I'm not.
One must compare.
I'll take them down if they mis-direct me.
Leo's conclusions will determine what I shall do.
"One thing is clear - in Biotechs, 95-99% of the times delay is bad news."
I'll take that as your opinion, as you do not sight a source. Fair enough.
Compare your quote to Eli Lilly's phase 2 Taltz study. Start date April, 2010. Primary completion date January, 2011(# patients=142).
Announcement of primary endpoint achievement, 3/29/12. Time for Eli Lilly to announce first endpoint(of 32 total endpoints(2 pe,30 sop)) in that trial was ~440 days. Eli Lillys product, Taltz. has been approved for the same target ipix is focusing on.
https://psoriasisclub.org/thread-638.html
https://clinicaltrials.gov/ct2/show/NCT01107457?term=ixekizumab&recrs=e&rslt=With&age=12&phase=1&rank=1
Lilly's analysis was much more detailed, with the 22nd endpoint being the longest(344 weeks(6.6 years)).
To date, psoriasis has been incurable(even given the taltz approval-responses vary-widely), and likely will continue to be for the foreseeable future.
Most past approved psoriasis drugs suffice for a limited time before a patient seeks another remedy due to diminishing results, or worsening ones.
George,
You state: "Prurisol could easily capture over 50% of the $9 Billion annual psoriasis market."
I'll counter your statement of "could".
What are the chances that it "will" capture over 50% of the $9 Billion annual psoriasis market?
You seem to be a betting man, based on your posts, and your above quoted statement(first paragarpgh).
Ha?
"There are many biotech companies doping favorable deals with big pharma after phase 2."
What do you mean by this? Please justify your statement.
Furthermore, you also state,"If IPIX fails to do a deal in the next few months, it will be a massive blow to the credibility of Leo. This will prove that Leo is the root of all evils at IPIX."
So, my interpretation of your post:
"Doping favorable deals is what BP, and all biotech's knowingly work toward"(I'll grant you a cybermich wink') is a bewildering statement(c.c M.Sullivan).
Interesting post day. Appears some early activity, followed by a siesta from ~ noon til 2:15 pm.
I guess a few birds tired, after gorging themselves, and spent the remainder (above noted time) roosting in their newly made nests.
Nice to hear them chirping again.Spring is in the air
froll,
You must of nmissed my post of Tuesday night(post #225965).
I broke down duration in days from last patient visit since trial. I compared duration to actual(final) patient enrollment to determine the average rate of patient enrollment per trial duration, which is last figure of each row with units shown as p/d(patients per day).
Hope that helps.
My Tuesday post ranking for duration was:
#1 Valeant .70p/d
#2 Kayowa .51p/d (they have rights to Brodalumab which was developed by Amgen, Inc. as AMG 827. AstraZeneca and Amgen took through ph3 trials but after of reports of patients having "events of suicidal ideation and behavior", Amgen threw that baby out. AstraZeneca gave rights in certain Asian territories such as Japan, where Kyowa Hakko Kirin has rights to brodalumab and continued as KHK4827, AstraZeneca then formed a partnership with Valeant in which Valeant took over exclusive rights to develop and commercialize brodalumab. Valeant has since sold off rights to Leo Pharma(no joke) to commercialize brodalumab in Europe. It been approved (since Feb 2017) in the U.S to treat moderate to severe plaque psoriasis in people who have not improved with other treatments.
There are many reasons why so many psoriasis patients(many of whom have partaken in clinical trials) were in involved with fda's 3/17/16 Patient Focused Drug Development for Psoriasis conference.
#3. IPIX (Innovation Pharmaceuticals) .51p/d
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=140321231
Can't argue history(doesn't mean some don't try).
LE is on the record.
Dan Sullivan has represented ipix (ctix at the time) and sucessfully defended their record.
His reputation,(I'm speaking of Dan Sullivan, whose hard work and dedication, I'd say he flies with the eagles) is on the line.
We'll see.
froll.
"Our trial size is relatively small ...." is a not accurate.
I've searched the completed ph 2 trials for moderate to severe plague psoriasis, which is what the Prurisol ph 2b is assessing, and can easily be reviewed at the clinicaltrials website. So far I've analyzed the first 27 of 67 studies shown.
Regarding patient trial size of those 27 trials, ipix draw of 199 patients is 7th highest, and enrollment rate is 6th highest. Total outcome measures of 11(ipix 2 pom's and 11 som's) wis tied even at 4th with 2 others(pfizer and astellas pharma at 11).
As Alfred E Neuman used to quip, "what, me worry?".
6M$bio,
"Prurisol P2b.. what do we know? Let’s start with it FAILED in P2a."
Then why did they fda approve ph2b?
I said I would not post it again but you convinced me otherwise. Listen (I doubt you will) to the attached link when the fda held the Focused Patient Drug Development conference in Washington D.C back on 3/17/16. which was attended in person by many psoriasis patients(also via phone and internet).
https://collaboration.fda.gov/p10ihzl1hdm/?launcher=false&fcsContent=true&pbMode=normal
Also, please refer to to the link below to my post yesterday comparing ipix(# 3 on my list) to 13 other ph 2 psoriasis trials.
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=140289370
The history of Brodalumab(administered via injection) still has legs even considering the following (in qoutes) from wikipedia:
"Brodalumab was developed by Amgen, Inc. as AMG 827.
In 2013 it was in two phase III clinical trials for the treatment of moderate to severe psoriasis.[4][5]
In November 2014, Amgen and AstraZeneca reported encouraging results for the compound. The companies stated that the compound met the primary endpoint showing superior skin clearance in a Phase III trial when compared to ustekinumab and a placebo.[6]
However, in May 2015, Amgen announced that it was ending its participation in co-development of the compound because of reports of patients having "events of suicidal ideation and behavior".[7] AstraZeneca will be solely responsible for any future development and marketing of brodalumab in all territories except for certain Asian territories such as Japan, where Kyowa Hakko Kirin has rights to brodalumab and continued as KHK4827.
In September 2015, AstraZeneca announced a partnership with Valeant Pharmaceuticals in which Valeant took over exclusive rights to develop and commercialize brodalumab.[8] In July 2016, the rights to commercialize brodalumab in Europe were sold to LEO Pharma.[9]
In January 2016, a biologics license application (BLA) was submitted to the US FDA.[10] Approval followed in February 2017.[3]"
Note, khk4827(brodalumab) is listed as #2 on my list(second link noted), and after investigating further, and as noted by wikipedia,it comes with a lot of issues.
If Prurisol performs as Dr Bertolino and LE seem to indicate, P will do well.
Listen to the patients urgency/concerns during that fda recorded meeting(first link above).
A none interest stoty I guess.
Anyway, for those arguing that P2b trial is inconsequential(not worthy of consideration) due to its "small enrollment numbers", of the 14 ph2 completed trials listed the average enrollment is ~129 patients vs ipix 199 patients.
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=140289370
Echo20,
"P could work wonders without all of the toxicity and troubles."
Could is right,don't know if it will work wonders, but I do think P along with some other medicines will exceed the "benefits" of Otezla.
Not sure if you saw this(my) post from a little while ago, but Valeant has 3 products in stage 3 psoriasis trials(not listed in the link below as I was trying to compare apples to apples(completed phase 2 psoriasis trials). You'll find my post below(listed in order from clinicaltrials, I rerragained the listed order from the site, based on figures given, to patients enrolled per day(I suspect patients and doctors want what is best).
IPIX ranks #3 of 14 by my matrix. #2 on the trial list(Kayowa) concluded 5 years ago. # 1((valeant) is a monster, but compare the outcome measures(they've bought out a few cos. for the psoriasis indication).
If Leo ain't lyin, as some suggest, we are golden(just on P). Time shall tell
Here's the list refereneced above:
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=140289370
Echo20,
"P could work wonders without all of the toxicity and troubles."
Could is right,don't know if it will work wonders, but I do think P along with some other medicines will exceed the "benefits" of Otezla.
Not sure if you saw this(my) post from a little while ago, but Valeant has 3 products in stage 3 psoriasis trials(not listed in the link below as I was trying to compare apples to apples(completed phase 2 psoriasis trials). You'll find my post below(listed in order from clinicaltrials, I rerragained the listed order from the site, based on figures given, to patients enrolled per day(I suspect patients and doctors want what is best).
IPIX ranks #3 of 14 by my matrix. #2 on the trial list(Kayowa) concluded 5 years ago. # 1((valeant) is a monster, but compare the outcome measures(they've bought out a few cos. for the psoriasis indication).
If Leo ain't lyin, as some suggest, we are golden(just on P). Time shall tell
Here's my post referenced above:
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=140289370
Echo20,
I replied to you about GWB and sepsis. Am I crossing messages?
None the less, I(think) I understand where you r coming from.
Psoriasis sucks(one of my brother in laws has to reckon with it-and does well-so to speak- he's very strong willed-but conditions, and time, can be burdensome).
I'm type 1 diabetic(38+ years) and, after listening to the 3/17/16 meeting between the fda panelists and psoriasis sufferers, I would not want to trade shoes.
Regarding blinding, you state:"normally it is done when there are safety issues and in case of very long trials such as Alz or cancer and they find that it is futile to proceed further.
This is a short trial - tge results may not be futile but may be not as attractive - safety was established so there was not need to unblind the data but maybe reason enough not to share."
1. If the trial is so short as you state, why do you pine about the long duration of result announcements(I can sympathize with you here, I ain't happy, but announcement of results have not been 'incredibly long")?
2. Results must be shared, good or bad, if material to share holders.
Echo20,
Advise the Bush family of Cytosorbents.
Noretreat,
"A question that will likely never be answered. Why is this taking so long will become moot if results are released."
ph2 mod to severe psoriasis comparisons(listed best to worst by patients enrolled per day:
listed by co.,drug,#pts,start date, end dt,last pt vis,duration(last vist-start),#pom's,#som's, avg pt enroll/d.
1.Valeant,idp-122,150pts,6/16,12/16,1/17,215d,1 pom,0 pom, .70p/d
2.Kayowa,khk4827,140pts,12/12,9/139/13,275d,1 pom, 8 som, .51p/d
3.IPIX,prurisol,199pts,11/16,12/17,12/17,396d,2 pom, 9 som,.50p/d
4.Pfizer,pf-06700841,212pts,12/16,3/18,3/18,474d,1 pom,10 som,.45p/d
5.forward ph.,fp187,252pts,9/10,1/12,5/12,609d,1 pom, 9 som, .41p/d
6.biocad,bcd-085,120pts,6/16,5/17,5/17,335d,1 pom,13 som,.36p/d
7.eli lilly,baricitnib,271pts,12/11,12/12,8/14,975d,1 pom, 21 som,.28p/d
8.promius ph.,dfd01,75pts,1/14,10/14,10/14,274d,1 pom,0 som,.27p/d
9.astellas,asp015k,124pts,3/10,7/11,7/11,488d,2 pom,3 som,.25p/d
10.idera,imo-3100,44pts,5/12,11/12,12/12,215d,1 pom,0som,.2p/d
11.bristol ms,bms582949,99pts,8/07,1/09,4/09,610d,1pom,3som,.16p/d
12.promius ph,dfd06,50pts,5/14,4/16,8/16,827d,1 pom,0 som,.06p/d
13.astellas,askp1240,60pts,4/12,6/14,1/15,1006d,4 pom,7 som,.06p/d
14.x.biotech,ra-18c3,8pts,9/11,7/12,8/12,336d,1 pom,6 som,.02p/d
pom denotes # of primary outcome measures, som denotes # secondary outcome measures.
I'm about 1/3-1/4 down the ph2 completed list, but will say ipix is right up there.
"As many pointed out, the long collection period is most likely due the surveys."
As far as I know the patients are not submitting an essay, they are being assessed by the doctors' and answering questions which recorded by doctors based based on the standards described in the outcome measures.(2 primary, 9 secondary).
I believe all that data is in hand it's then a matter making a spread sheet of sorts, entering each patients data on the spread sheet, and analyze the outcome measures. Hopefully the majority falls in the good with no bad or uglies recorded.